Bafna PharmaceuticalsNSE:BAFNAPH +5.00%59 PB Ratio is 4.79 as of Jun. 26, 2026, which is 75% above its 10-year median of 2.73. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 59/100 and a GF Value™ of ₹90.56 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 81.02% on this metric.
The historical rank and industry rank for Bafna Pharmaceuticals's PB Ratio or its related term are showing as below:
NSE:BAFNAPH'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 2.73 Max: 7.48
Current: 4.88
During the past 13 years, Bafna Pharmaceuticals's highest PB Ratio was 7.48. The lowest was 0.43. And the median was 2.73.
NSE:BAFNAPH's PB Ratio is ranked worse than 81.02% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs NSE:BAFNAPH: 4.88
During the past 12 months, Bafna Pharmaceuticals's average Book Value Per Share Growth Rate was 13.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bafna Pharmaceuticals was 48.10% per year. The lowest was -36.20% per year. And the median was 9.40% per year.
Back to Basics: PB Ratio
Bafna Pharmaceuticals (NSE:BAFNAPH) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a PB Ratio of 4.79 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bafna Pharmaceuticals and its competitors. This is 75% above median its historical median of 2.73. Over the past decade, Bafna Pharmaceuticals' PB Ratio has ranged from 0.43 to 7.48. According to the industry distribution chart, Bafna Pharmaceuticals ranks #747 out of 922 companies in the Drug Manufacturers industry, placing it in the top 81%.
Is Bafna Pharmaceuticals' PB Ratio too high?
Bafna Pharmaceuticals' current PB Ratio of 4.79 is 75% above median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 7.48. The Drug Manufacturers industry median PB Ratio is 1.86. Bafna Pharmaceuticals' value of 4.79 is 158.2% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #747 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #747 out of 922 companies for PB Ratio. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.86. Bafna Pharmaceuticals' value of 4.79 is 158.2% above this benchmark. Historically, Bafna Pharmaceuticals' own PB Ratio has ranged from 0.43 to 7.48 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 1.86, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current PB Ratio of 4.79 is 158.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current PB Ratio is 4.79, which is 75% above median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.56, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current PB Ratio is 4.79, which is 75% above median its 10-year median of 2.73 and 158.2% above the Drug Manufacturers industry median of 1.86. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current PB Ratio is 4.79 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.56.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
PB Ratio: 4.79 (75% above median its 10-year median of 2.73)
GF Value™: ₹90.56 vs. price of ₹194.68 (115% above fair value)
Industry Position: 158.2% above the Drug Manufacturers median (#747 of 922)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score
Get the complete analysis for NSE:BAFNAPH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
